04/09/2019

EuBiologics inaugurates 2nd manufacturing plant in Chuncheon, Korea

Dr. Baik Yeong-Ok, CEO of EuBiologics, and Dr. Jerome Kim, Director General of IVI pose together at the inauguration of EuBiologics’ Second Plant in Chuncheon, Korea on April 9, 2019.   EuBiologics, the manufacturer of Euvichol® and Euvichol-Plus® oral cholera vaccine, and an important partner […]
04/12/2019

Experts find evidence of underfunding in rheumatic heart disease research

IVI’s Director General, Dr. Jerome Kim was a member of the team of experts that looked at the underfunding of rheumatic heart disease (RHD) research.   RHD, a long-term consequence of Streptococcus pyogenes (Group A streptococcus, or GAS) infection, is estimated to affect at least 33 […]
04/17/2019

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

– Grant from the Bill & Melinda Gates Foundation will support additional supply of novel TCV at affordable cost for public sector markets   SEOUL, Korea –The International Vaccine Institute (IVI) announces receipt of a $15.7 million-dollar grant from the Bill & Melinda Gates Foundation […]
04/18/2019

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

SEOUL, South Korea — An international consortium, led by the International Vaccine Institute (IVI), has received funding from the UK’s Fleming Fund Regional Grants to conduct the Capturing Data on Antimicrobial Resistance (AMR) Patterns and Trends in Use in Regions of Asia (CAPTURA) project. The […]